Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Sarcoma, Myeloid 1Leukemia, Myeloid, Acute 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 34Vincristine 23Methotrexate 21blinatumomab 20Prednisone 20Specimen Handling 19Cytarabine 18merphos 16prednylidene 15deltacortene 15Mercaptopurine 15Doxorubicin 15Dexamethasone 15Biopsy 15pegaspargase 13N,N-dicyclohexyl-isoborneol-10-sulfonamide 13azathiopurine 12Rituximab 12Etoposide 12dexamethasone acetate 11dexamethasone 21-phosphate 11auricularum 11Spinal Puncture 11Leucovorin 11Calcium Dobesilate 11Asparaginase 11fludarabine 10Thioguanine 9Magnetic Resonance Spectroscopy 9Inotuzumab Ozogamicin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Burkitt Lymphoma × Leyk × 90 days × Clear all
NCT02101853 2026-06-03

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
669 enrolled 14 charts
Lymphoid

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡